| Plenary 1: The 2030 SDG: what does this mean for viral hepatitis? | 11:00 - 11:20 Reducing HBV and HCV prevalence - where do we stand and what is required to improve? 11:20 - 11:40 Is an HBV cure required to stop the increasing death toll of hepatitis B? 11:40 - 12:10 Can human infection models help us to develop an HCV vaccine? |
| Intrahepatic immune responses | 14:00 - 14:15 A new immune niche in the liver 14:20 - 14:35 Activation of T cells in the human liver |
| Hepatitis B: Current therapies | 14:00 - 14:15 Whom to treat und whom not to treat 14:20 - 14:35 Stopping NA: Oppotunities and Risks |
| Hepatitis Delta | 16:00 - 16:15 Bulevirtide: Update on RW-Studies 16:20 - 16:35 Novel Treatments in Development |
| HEV | 16:00 - 16:15 Stem-cell derived hepatocytes to study HEV infection 16:20 - 16:35 HEV infection in immunosuppressed patients |
| Animal models for hepatitis research | 8:30 - 8:45 Humanized mouse models: what is their limitation? 8:50 - 9:05 Immunocompetent animal models |
| Hepatitis E | 8:30 - 8:45 Hepatitis E in Africa and Asia 8:50 - 9:05 Hepatitis E in Western Countries |
| Plenary 2: Novel therapies - challenges and opportunities | 10:30 - 10:50 Options for HBV / HDV targeting drugs 10:50 - 11:10 New developments in treating viral hepatitis - where does industry go? 11:10 - 11:30 What is required to implement a new therapy? |
| MASLD & HCC | 13:30 - 13:45 Immune pathogenesis in MASLD 13:50 - 14:05 Immune signatures guiding Tx decisions in HCC |
| HBV cure: Novel treatments | 13:30 - 13:45 ASOs and siRNAs 13:50 - 14:05 CAMs and other Targets |
| Long-acting antivirals | 15:30 - 15:45 Novel deveopments in the field of long-lasting antivirals 15:50 - 16:05 Efficacy and adherence in the setting of PWID |
| Metabolic health and viral hepatitis | 15:30 - 15:45 MetHBV: additional risk to progress 15:50 - 16:05 MetHBV: is there really an increased HBsAg loss rate? |
| Plenary 3: Optimizing trial designs to achieve real impact | 9:00 - 9:20 Challenges and pitfalls in prophylactic vaccine trials on HEV/HCV 9:20 - 9:40 Rethinking end points and clinical trial design 9:40 - 10:00 Performing clinical trials in Africa |
| Addressing the gap in diagnosis and Tx access | 10:30 - 10:45 Identifying the missing link... 10:50 - 11:05 App-based treatment guidance |
| RNA viruses and innate immunity | 10:30 - 10:45 Innate immune recognition of HDV 10:50 - 11:05 HAV vs. HCV: differences in innate immune activation |
| Plenary 4: What does understanding immunology mean for combating viral hepatitis? | 14:00 - 14:20 How can we best design clinical trials to monitor immune responses? 14:20 - 14:40 T-cell responses in viral hepatitis B and C 14:40 - 15:00 Bepirovirsen - does the linical response rely on triggering immunity? |
